ReviewCancers2021
Vitreoretinal Lymphoma.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- Efficacy and Safety of Response-Adapted Intravitreal Methotrexate Therapy for Vitreoretinal Lymphoma: A Two-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Diagnostic Yield of Vitreous Biopsy and MYD88 Mutation Analysis in Vitreoretinal Lymphoma: A Retrospective Cohort Study.Ocular oncology and pathology · 2026Article
- Retinal vasculitis as a presenting sign of Epstein-Barr virus positive diffuse large B-cell lymphoma: a case report.BMC ophthalmology · 2026Article
- Primary vitreoretinal lymphoma: diagnostic and therapeutic insights from a Slovenian population-based study.International journal of retina and vitreous · 2026Article
- Primary Central Nervous System Lymphoma as a Masquerade of Uveitis: A Case Report of Ocular Involvement.Cureus · 2026Article
- Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma.Scientific reports · 2026Article
- Interpretable Deep Learning for OCT-Based Diagnosis of Vitreoretinal Lymphoma Versus Uveitis.Translational vision science & technology · 2026Article
- DECODE VRL Report No. 1: Lymphocyte Survival After Diagnostic Vitrectomy - Does Size Matter?Translational vision science & technology · 2026Article
- Posterior segment imaging clues to systemic malignancy: a phenotype-to-confirmation narrative review.Frontiers in ophthalmology · 2026Review
- Vitrectomy as a rapid diagnostic tool for lymphoma: Cytology and flow cytometry approach.British journal of haematology · 2025Article
- Vitreoretinal lymphoma presenting as amaurosis fugax.American journal of ophthalmology case reports · 2025Article
- A case of primary intraocular B-cell lymphoma masquerading alongside varicella-zoster virus retinitis.American journal of ophthalmology case reports · 2025Article
- Retromode imaging in vitreoretinal lymphoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Role of miRNA in adult ocular tumorigenesis.Frontiers in molecular biosciences · 2025Review
- Intraocular Lymphoma: A Review.Journal of ophthalmic & vision research · 2025Review
- FACTORS ASSOCIATED WITH DELAYED DIAGNOSIS IN PATIENTS WITH PRIMARY VITREORETINAL LYMPHOMA.Retina (Philadelphia, Pa.) · 2024Article
- Multimodal imaging in a case of presumed secondary vitreoretinal lymphoma presenting with inner retina and optic nerve head infiltration.American journal of ophthalmology case reports · 2024Article
- Epstein-Barr virus-positive iris diffuse large B-cell lymphoma detected by metagenomic next-generation sequencing.BMC ophthalmology · 2024Article
- Case report: Intraretinal hyperflow microinfiltration lesions on swept-source optical coherence tomography angiography as a potential biomarker of primary vitreoretinal lymphoma.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitreoretinal lymphoma (VRL) is a rare variant of primary central nervous system lymphoma (PCNSL), mostly of diffuse large B cell lymphoma, which affects the retina and/or the vitreous with or without optic nerve involvement. The disease course is aggressive. Up to 90% of the patients develop central nervous system lymphoma within one year. The diagnosis of VRL is challenging due to nonspecific chronic and relapsing uveitis and is made by anterior chamber tab or vitreous aspirate biopsy. There is no established treatment protocol for VRL patients with bilateral involvement without CNS involvement. There are suggestions to use only intravitreal chemotherapy with methotrexate and/or rituximab. Alternatively, systemic high-dose MTX treatment or external beam radiotherapy is used. Further studies are needed to prove and confirm the prophylactic systemic therapy in preventing CNS involvement in limited VRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.